Parkman Healthcare Partners LLC Has $2.59 Million Holdings in Insmed Incorporated (NASDAQ:INSM)

Parkman Healthcare Partners LLC decreased its position in shares of Insmed Incorporated (NASDAQ:INSM) by 55.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,433 shares of the biopharmaceutical company’s stock after selling 44,838 shares during the period. Parkman Healthcare Partners LLC’s holdings in Insmed were worth $2,587,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of INSM. Comerica Bank boosted its stake in Insmed by 3,984.1% during the 1st quarter. Comerica Bank now owns 49,540 shares of the biopharmaceutical company’s stock valued at $1,344,000 after purchasing an additional 48,327 shares during the period. CWM LLC grew its stake in shares of Insmed by 11.0% in the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 155 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Insmed during the second quarter worth $256,000. Envestnet Portfolio Solutions Inc. acquired a new position in Insmed during the 2nd quarter valued at $330,000. Finally, Ariston Services Group acquired a new stake in Insmed in the 2nd quarter worth $201,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on INSM. Truist Financial reaffirmed a “buy” rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Bank of America raised their price objective on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. TD Cowen boosted their price objective on Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a research report on Friday, August 9th. UBS Group upped their target price on Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Insider Activity at Insmed

In related news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now owns 106,134 shares of the company’s stock, valued at approximately $7,951,559.28. This trade represents a 11.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the sale, the insider now owns 100,100 shares of the company’s stock, valued at $7,157,150. This trade represents a 27.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 78,882 shares of company stock worth $5,765,446 in the last ninety days. Company insiders own 4.60% of the company’s stock.

Insmed Trading Up 0.0 %

Shares of NASDAQ INSM opened at $72.43 on Wednesday. The company’s 50 day simple moving average is $72.21 and its 200 day simple moving average is $69.01. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The firm has a market capitalization of $12.96 billion, a P/E ratio of -13.05 and a beta of 1.10.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. During the same period in the previous year, the business posted ($1.10) earnings per share. The firm’s revenue for the quarter was up 18.1% compared to the same quarter last year. On average, analysts predict that Insmed Incorporated will post -5.44 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.